Form 4: Anika Therapeutics Director Susan Vogt Receives Significant RSU Grant

Anika Therapeutics, Inc. Director Susan L.N. Vogt was granted 14,164 restricted stock units (RSUs) on June 20, 2025, increasing her beneficial ownership to 50,213 shares.

Summary

• Susan L.N. Vogt, a Director of Anika Therapeutics, Inc. (ANIK), acquired 14,164 shares of common stock on June 20, 2025.
• These shares were granted as Restricted Stock Units (RSUs) at a price of $0 per share, indicating an equity compensation award.
• Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting.
• Following this transaction, Ms. Vogt's total beneficial ownership in Anika Therapeutics, Inc. increased to 50,213 shares.
• The RSUs are scheduled to vest in full on the earlier of the Company's 2026 annual meeting of stockholders or June 20, 2026.

Sentiment

Score: 7

Explanation: The grant of equity compensation to a director is generally a positive signal, indicating alignment of interests and commitment. It's a routine event, so not highly impactful, but certainly not negative.

Positives

• The grant of 14,164 Restricted Stock Units (RSUs) to Director Susan L.N. Vogt aligns her interests with those of shareholders, incentivizing long-term performance and value creation.
• The increase in beneficial ownership to 50,213 shares demonstrates continued commitment and a vested interest from a key board member in the company's future success.

Negatives

• No specific negative points are identified in this Form 4 filing, as it primarily reports a routine equity grant.

Risks

• The value of the granted Restricted Stock Units (RSUs) is directly tied to the future performance of Anika Therapeutics' common stock price, meaning their ultimate value to the recipient is subject to market fluctuations.

Future Outlook

The 14,164 Restricted Stock Units granted to Director Susan L.N. Vogt are scheduled to vest in full on the earlier of the Company's 2026 annual meeting of stockholders or June 20, 2026, indicating a future milestone for this equity compensation.

Industry Context

This Form 4 filing reports a routine equity compensation grant to a director, which is a common practice across publicly traded companies, particularly in the medical technology sector, to align management and board interests with shareholder value. It does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a standard form of equity compensation in publicly traded companies, aligning director incentives with long-term shareholder value.
• The vesting schedule, tied to a future annual meeting or a specific date, is typical for such grants, similar to practices at comparable companies in the biotechnology or medical device sectors.
• The specific number of RSUs (14,164) and the resulting beneficial ownership (50,213 shares) would need to be compared against compensation practices and ownership levels of directors at peer companies within the medical technology industry to assess if it is above, below, or in line with industry benchmarks. This document does not provide the necessary context for such a detailed comparison.

Related Party Transactions

• The grant of 14,164 Restricted Stock Units (RSUs) to Susan L.N. Vogt, a Director of Anika Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with long-term shareholder value, potentially leading to more focused decision-making aimed at increasing stock price.

Next Steps

• The 14,164 Restricted Stock Units (RSUs) are expected to vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026.

Key Dates

Keywords

Anika Therapeutics, ANIK, SEC Form 4, Restricted Stock Units, RSU grant, insider transaction, beneficial ownership, director compensation, equity compensation, Susan Vogt